- UniQure (QURE +13.1%) shoots higher after B. Riley FBR initiates coverage with a Buy rating and a $50 price target, believing that AMT-061 has the potential to dominate the hemophilia B adeno-associated virus gene therapy space.
- In particular, success in a dose confirmation guided to start by the end of Q2, with a readout expected by year-end 2018, potentially could be a key inflection point for QURE shares, the firm says.
- QURE announced earlier today that it has enrolled its first patient in a Phase 3 HOPE-B pivotal study of AMT-061.
- The firm also starts Sorrento Therapeutics (SRNE +5.1%) with a Buy rating and a $14.25 target, saying SRNE is leveraging its proprietary technological expertise, which includes one of the world's most robust fully human monoclonal antibody libraries, to develop novel chimeric antigen receptor T-cell treatments.
- Now read: Spark's Gene Therapy For Hemophilia B Looks To Change Up The Game
Original article